How BI Supports Grass Roots Innovation
Hear from life-science entrepreneurs about how we are supporting early-stage science through our innovative Grass Roots program.
Search
"Medical innovations and healthcare for everyone"
African Americans are often excluded from healthcare options and medical innovations. We want to learn how we can better serve them.
Breakthrough introduction innovation pet parasiticides
In 2014, Boehringer introduced a new product, which became the first in a new class of isoxazoline products for flea and tick protection in dogs.
1990-2023: Value through Innovation
The Boehringer Ingelheim history from 1990 to 2023, with milestones
Innovation from within
Justine Rochon and Marc Weimer talk about the transformation of Biostatistics and Data Sciences (BDS) into a modern organisation in drug development.
Advancing green chemistry for more sustainable medicines
By applying the principles of eco-design and green chemistry, we developed an innovative manufacturing process with reduced environmental footprint.
Innovation in medicinal chemistry
Darryl McConnell, Research Site Head, Austria and Jürgen Mack, Medicinal Chemistry, explain how we are working to unlock unsolved diseases
Combating food insecurity for more health equity in the U.S.
Meet social innovation founder Katie at Making More Health Together 2023: How the social innovation founder brings fresh food stores back to the U.S.
Innovation & Opportunity for Tech in Pharma
Boehringer Ingelheim’s Meet & Greet at the Women in Tech Global Conference
Digital innovation: „We change the way labs work“
QUDA – an in-house software – changes the way labs work. It increases our quality assurance and our drug saftey.
Building blocks of our future
Our global investment projects are the building blocks for improved healthcare and sustainability
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
Brigitte Fuhr
Brigitte Fuhr on constant innovation
Simon Manyara
Simon Manyara on constant innovation
Liliana Montano
Liliana Montano on constant innovation
New Partnership to Develop Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
Cardio-Renal-Metabolic Research
Read about our patient-centric approach to cardio-renal-metabolic disease research.
Partnering
Partnering
Innovating for our business
We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.
BIVF funding more than doubled to 250 M€
Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
commitments to sustainable development
On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
RE-LY-trial-publication-10-year-anniversary
Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases